
SynBioBeta Speaker
Nabiha Saklayen
Cellino Bio
CEO & Co-founder
Dr. Nabiha Saklayen, PhD is the CEO and co-founder of Cellino, building the manufacturing tech stack that will make your own cells the most powerful medicine you've ever had access to. She earned her PhD in physics from Harvard as an HHMI Fellow, where she invented the laser technology at the heart of Cellino's platform, and has been recognized as a Pioneer on MIT Tech Review's 35 Innovators Under 35 and a Forbes 30 Under 30 in Healthcare. She's a TED speaker, a World Economic Forum Global Innovator, a member of the National Academies Forum on Regenerative Medicine, and the inaugural Tory Burch Foundation Fellow in Genomics at the Innovative Genomics Institute. Born in Saudi Arabia to Bangladeshi parents and raised in Germany and Sri Lanka, she co-created I Am A Scientist, an educational program now running in all 50 states. Her mission is straightforward: your cells are the cure, and the only thing that's been missing is the infrastructure to deliver them at scale.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Nabiha
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon






























































































































































































































































































































